ArticleMedicine2026
Comparative study of piperacillin-tazobactam versus ampicillin in the treatment of severe pneumonia in children: A retrospective study.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Severe pneumonia remains a leading cause of pediatric mortality, with increasing β-lactamase-producing pathogens challenging traditional penicillin efficacy. This study compared the clinical efficacy and safety of piperacillin-tazobactam (PT) versus ampicillin (AMP) in children with severe community-acquired pneumonia (CAP). This retrospective cohort study with propensity score matching (PSM) enrolled children aged 6 months to 5 years with severe CAP from January 2022 to June 2024. After 1:1 PSM, 95 children per group received either PT or AMP. Primary endpoints included early clinical failure rate, end-of-therapy clinical cure rate, and sustained clinical success at test of cure (TOC). Secondary endpoints encompassed symptom resolution time, pathogen eradication rate, and safety profile. The PT group demonstrated significantly lower early clinical failure rate (2.11% vs 9.47%, P = .030; RR = 0.22, 95% CI: 0.05-0.98) and higher end-of-therapy clinical cure rate (88.17% vs 76.74%, P = .044) compared with AMP. PT achieved superior overall pathogen eradication (88.73% vs 73.13%, P = .019), particularly for Haemophilus influenzae (95.83% vs 68.00%, P = .012) and Pseudomonas aeruginosa (100.00% vs 40.00%, P = .038). Hospital stay was shorter in the PT group (8.65 ± 2.30 vs 9.81 ± 2.73 days, P = .002). Adverse event rates were comparable (10.53% vs 9.47%, P = .809). Piperacillin-tazobactam demonstrated superior efficacy over ampicillin for severe pediatric CAP, with comparable safety. These findings suggest PT offers a favorable benefit-risk profile for severe pediatric CAP, particularly in areas with documented β-lactamase-producing bacterial prevalence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.